Oral pills may help keep weight off after stopping popular injections

NCT ID NCT07729332

Not yet recruiting Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This study tests whether switching to an oral weight-loss medication—either phentermine or orforglipron—can help people maintain weight loss after they stop taking injectable GLP-1 drugs like semaglutide or tirzepatide. Participants must have lost at least 10% of their body weight on the injectable therapy. The trial will compare the two oral options over six months to see which better prevents weight regain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: phentermine or orforglipron oral tablets
What this could lead to: If successful, this could offer a practical way to maintain weight loss after stopping popular injectable GLP-1 drugs, reducing the need for lifelong injections.
What could go wrong: This is a small, early-phase trial with only 60 participants, so results may not apply broadly. Both phentermine and orforglipron have side effects, and weight regain may still occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.